|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
EBSCO_ocn972010894 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr ||||||||||| |
008 |
180410s2012 nyua ob 001 0 eng |
010 |
|
|
|a 2017285162
|
040 |
|
|
|a DLC
|b eng
|e rda
|e pn
|c DLC
|d YDX
|d YDXCP
|d N$T
|d E7B
|d EBLCP
|d DEBSZ
|d D6H
|d AGLDB
|d OCLCF
|d LVT
|d DKU
|d SNK
|d BTN
|d INTCL
|d MHW
|d AUW
|d OCLCQ
|d VNS
|d VTS
|d OCLCO
|d AU@
|d S8J
|d S9I
|d M8D
|d OCLCO
|d A6Q
|d OCLCQ
|d K6U
|d OCLCA
|d OCLCQ
|d AJS
|d OCLCO
|d OCLCQ
|
019 |
|
|
|a 828140652
|a 923653298
|a 972077327
|a 1009010894
|a 1038970890
|a 1058906962
|a 1083625878
|a 1096231689
|a 1105788038
|
020 |
|
|
|a 9781619423206
|q (eBook)
|
020 |
|
|
|a 1619423200
|
020 |
|
|
|a 1619423162
|
020 |
|
|
|a 9781619423169
|
020 |
|
|
|z 9781619423169
|q (hardcover)
|
029 |
1 |
|
|a DEBBG
|b BV043774742
|
029 |
1 |
|
|a DEBSZ
|b 472770934
|
035 |
|
|
|a (OCoLC)972010894
|z (OCoLC)828140652
|z (OCoLC)923653298
|z (OCoLC)972077327
|z (OCoLC)1009010894
|z (OCoLC)1038970890
|z (OCoLC)1058906962
|z (OCoLC)1083625878
|z (OCoLC)1096231689
|z (OCoLC)1105788038
|
042 |
|
|
|a pcc
|
050 |
0 |
0 |
|a RC889
|b .E7525 2012
|
060 |
|
4 |
|a WJ 709
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
0 |
|a 616.6/922
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Erectile dysfunction :
|b causes, risk factors, and management /
|c Paul Steven Grant, editor.
|
264 |
|
1 |
|a New York :
|b Nova Biomedical, Nova Science Publishers, Inc.,
|c [2012]
|
264 |
|
4 |
|c Ã2012
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Human sexuality
|
490 |
1 |
|
|a Sexology research and issues
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a ERECTILE DYSFUNCTION -- ERECTILE DYSFUNCTION -- Contents -- Foreword -- Part One -- Introduction -- References -- A Primary Care Approach to Erectile Dysfunction -- Abstract -- Introduction -- Assessment of ED -- Common Causes of Erectile Dysfunction -- Baseline Investigations -- Men in the Following Categories Require Referral -- Developing a Treatment Plan -- Phase 1: Stabilise General Clinical Condition -- Phase 2: Treat Correctable Causes -- Phase 3: Initiate Specific Therapy for Erectile Dysfunction -- Phase 4: Onward Referral
|
505 |
8 |
|
|a Conclusion References -- Erectile Dysfunction: Causes, Risk Factors and Management -- Abstract -- Introduction -- Epidemiology -- Physiology of Erection -- Pathophysiology of Erectile Dysfunction -- Psychogenic ED -- Neurogenic ED -- Hormonal Causes of ED -- Vascular Causes of ED -- Drug-Induced Erectile Dysfunction -- Erectile Dysfunction due to other Systemic Diseases and Ageing -- Renal Disease -- Spinal Cord Injury -- Correlations of ED with CAD and DM -- Correlation of ED with Lower Urinary Tract Symptoms (LUTS)
|
505 |
8 |
|
|a Clinical Evaluation Quantification of the Severity of Erectile Dysfunction and Improvement -- Physical Examination -- Laboratory Studies -- Special Studies -- Penile Duplex Doppler Imaging -- Management of Erectile Dysfunction -- I. Medical and other Non-surgical Treatment -- Phosphodiesterase Type 5 Inhibitors (PDE5 Inhibitors) -- 1. Sildenafil Citrate (Viagra) -- 2. Vardenafil (Levitra) -- 3. Tadalafil (Cialis) -- 4. Use of PDE5 Inhibitors and Cardiovascular Safety -- Apomorphine (Uprima) -- Adrenergic-Receptor Antagonists
|
505 |
8 |
|
|a 1. Phentolamine (Regitine) 2. Yohimbine -- Trazodone (Desyrel, Mesyrel) -- Dietary Supplements and Erectile Dysfunction -- 1. Ginkgo Bilboa -- 2. L-Arginine -- Intracavernosal and Intraurethral Therapy -- 1. Alprostadil (Prostaglandin E1, Caverject, Medicated Urethral System for Erection) -- 2. Papaverine -- 3. Phentolamine (Regitine) -- 4. Moxisylyte Chlorohydrate -- 5. Chlorpromazine (Thorazine) -- 6. Vasoactive Intestinal Polypeptide (VIP) -- Testosterone -- Vacuum Constrictive Device -- II. Surgical Treatment
|
505 |
8 |
|
|a Penile Prostheses Implantation Penile Revascularization -- Venectomy -- III. Future Treatments -- Gene Therapy -- 1. Gene Therapy and NOS -- 2. Gene Therapy and the Human Calcium-Sensitive Potassium Channel Subtype -- 3. Gene Therapy and Vascular Endothelial Growth Factor (VEGF) and other Molecular Targets -- Conclusion -- References -- Current and Emerging Novel Diagnostic Tools for the Diagnosis of Male Erectile Dysfunction -- Abstract -- Introduction -- Consensus and Major International Guidelines on the Investigations of ED
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Impotence.
|
650 |
1 |
2 |
|a Erectile Dysfunction
|
650 |
|
6 |
|a Impuissance sexuelle.
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Impotence.
|2 fast
|0 (OCoLC)fst00968233
|
700 |
1 |
|
|a Grant, Paul Steven,
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Erectile dysfunction.
|d New York : Nova Science Publishers, [2012]
|z 9781619423169
|w (DLC) 2012938162
|
830 |
|
0 |
|a Human sexuality.
|
830 |
|
0 |
|a Sexology research and issues.
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540911
|z Texto completo
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3017697
|
938 |
|
|
|a ebrary
|b EBRY
|n ebr10654668
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 540911
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 7311779
|
994 |
|
|
|a 92
|b IZTAP
|